Navigation Links
Neuralstem President And CEO To Present At The 2013 Rodman & Renshaw Annual Healthcare Conference
Date:9/3/2013

/span> disease, in February 2013, and has received FDA approval to begin Phase II. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord injury in January 2013.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions.  The company is in the last cohort of a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include traumatic brain injury (TBI), Alzheimer's disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information                                                      

This news release may contain forward-looking
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
10. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
11. Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 WIRB-Copernicus Group ® ("WCG")™, ... review services for clinical research, announced today that ... of Richmond, VA -based Alliance ... biosecurity consulting firm in the United ... division – WCG Biosafety™ – will be able ...
(Date:7/24/2014)... Canada (PRWEB) July 24, 2014 The ... Optimizing Dose Escalation in First in Human Studies” will ... make better go/no-go decisions. , With increasing R&D costs ... pharmaceutical companies need to maximize the knowledge collected in ... decisions and improve success in late stage development. , ...
(Date:7/24/2014)... 24, 2014  Spherix Incorporated (SPEX) -- an intellectual ... of intellectual property, today announced that the Company will ... 30, 2014 on Monday, August 18, 2014 for shareholders. ... ET on Monday, August 18, 2014 to discuss the ... company,s CEO, Anthony Hayes . Following ...
(Date:7/24/2014)... 24, 2014 As part of the ... in the MENA region during 2014 with potential global ... provider agreement with DZS to manage our clinical trials ... Global VP of R&D and President of SBI pharmaceuticals ... operational practices with a focus on utilizing eClinical software ...
Breaking Biology Technology:WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 2WIRB-Copernicus Group Announces Acquisition of Alliance Biosciences; Executives Join WCG Biosafety Division 3Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Spherix Schedules Shareholder Update Call 2SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... Ohio, July 8 Knowledge Enterprises, Inc.,and ... release of The,2007-2008 Orthopaedic Industry Annual Report, ... industry data. The nearly 200,page Annual Report ... to Joint Replacement, Fracture Repair, Arthroscopy/Soft,Tissue Repair, ...
... July 8 RADI Medical Systems today,announced ... guide,wire, PressureWire(R) Certus, which will begin shipments ... The latest generation of the PressureWire(R) ... which provides three key,advantages for physicians. The ...
... July 8 Telik, Inc.,(Nasdaq: TELK ), ... &,Medicinal Chemistry Letters describing a novel class of ... new treatment for diabetes.,These unique compounds are the ... to optimize the original lead structure identified through,the ...
Cached Biology Technology:Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report 2RADI Medical Systems Launches Next Generation PressureWire(R) Certus 2Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters 2
(Date:7/24/2014)... of researchers led by the University of York has ... in the Western Indian Ocean. , The results, ... to a revolution in the management of marine protected ... than 11,000 km in the region now under ... zones of the seas and coasts designed to protect ...
(Date:7/24/2014)... Singapore have developed Asia,s first genetic test for identifying ... the cornea called corneal stromal dystrophy which can lead ... the POLARIS TGFBI (Transforming Growth Factor beta Induced) test, ... diagnosis and management of patients with corneal stromal dystrophies. ... mutation who may also be at risk of developing ...
(Date:7/23/2014)... new study of identical twins has found that early ... study, in the journal Child Development , was ... King,s College London. , "Since reading is an ability ... reading instruction," according to Stuart J. Ritchie, research fellow ... the study. "Early remediation of reading problems might aid ...
Breaking Biology News(10 mins):Western Indian Ocean communities play vital role in conservation 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3Stronger early reading skills predict higher intelligence later 2
... may plead, cajole or entice their children to try new foods, ... University of North Carolina at Chapel Hill reveals that the reason ... on their plate and more to do with their genes. ... at UNC,s Gillings School of Global Public Health, adds to the ...
... scientists led by Dr Kate Sanders from the University of ... Museum, has uncovered how some sea snakes have developed ,shrunken ... Their research is published today in the journal ... "all the better to eat you with" - would ...
... DNA sequence data is growing exponentially", says Miami University ... the genes that we identify, we have no idea ... a foreign language, waiting to be deciphered." Understanding the ... at the forefront of molecular biology. Many groups develop ...
Cached Biology News:Genes may be reason some kids are picky about food 2Scientists discover reasons behind snakes' 'shrinking heads' 2Genomic data are growing, but what do we really know? 2
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood CD8+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Umbilical cord blood CD4+ T cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Biology Products: